Arca Biopharma Overview
- Year Founded
-
1992
- Status
-
Acquired/Merged
- Employees
-
5
- Latest Deal Type
-
M&A
Arca Biopharma General Information
Description
Operator of a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Contact Information
Website
www.arcabio.comCorporate Office
- 10170 Church Ranch Way
- Suite 100
- Westminster, CO 80021
- United States
Corporate Office
- 10170 Church Ranch Way
- Suite 100
- Westminster, CO 80021
- United States
Arca Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Merger/Acquisition | 29-Aug-2024 | Completed | Generating Revenue | |||
| 12. 2PO | 02-Apr-2021 | Cancelled | Generating Revenue | |||
| 11. PIPE | 03-Jun-2020 | Completed | Generating Revenue | |||
| 10. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 9. PIPE | 15-Jun-2015 | Completed | Clinical Trials - Phase 2 | |||
| 8. PIPE | 20-Feb-2014 | Completed | Generating Revenue | |||
| 7. PIPE | 17-Jun-2013 | Completed | Generating Revenue | |||
| 6. PIPE | 18-Apr-2011 | Completed | Generating Revenue | |||
| 5. Grant | 04-Nov-2010 | $489K | $33.2M | Completed | Generating Revenue | |
| 4. Reverse Merger | 28-Jan-2009 | $33.2M | Completed | Startup |
Arca Biopharma Comparisons
Industry
Financing
Details
Arca Biopharma Competitors (11)
One of Arca Biopharma’s 11 competitors is CytoAgents, a Venture Capital-Backed company based in Pittsburgh, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytoAgents | Venture Capital-Backed | Pittsburgh, PA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| CyTuVax | Venture Capital-Backed | Maastricht, Netherlands | ||||
| Merck & Co. | Corporation | Rahway, NJ |
Arca Biopharma Patents
Arca Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3101700-A1 | Methods and compositions involving bucindolol for the treatment of atrial fibrillation | Pending | 25-May-2018 | ||
| EP-3691635-A2 | Methods and compositions involving bucindolol for the treatment of atrial fibrillation | Active | 25-May-2018 | ||
| EP-3691635-A4 | Methods and compositions involving bucindolol for the treatment of atrial fibrillation | Active | 25-May-2018 | ||
| EP-3691635-B1 | Methods and compositions involving bucindolol for the treatment of atrial fibrillation | Active | 25-May-2018 | ||
| EP-4275684-A1 | Methods and compositions involving bucindolol for the treatment of atrial fibrillation | Pending | 25-May-2018 | A61K31/4045 |
Arca Biopharma Signals
Arca Biopharma Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atlas Venture | Venture Capital | Minority | ||
| Boulder Ventures | Venture Capital | Minority | ||
| InterWest Partners | Venture Capital | Minority | ||
| New Enterprise Associates | Venture Capital | Minority | ||
| New Leaf Venture | Venture Capital | Minority |
Arca Biopharma Investments & Acquisitions (3)
Arca Biopharma’s most recent deal was a Reverse Merger with Oruka Therapeutics for . The deal was made on 29-Aug-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Oruka Therapeutics | 29-Aug-2024 | Reverse Merger | Biotechnology | ||
| Nuvelo | 27-Jan-2009 | Merger/Acquisition | Drug Discovery | ||
| Viridian Therapeutics | 05-Feb-2008 | Seed Round | Drug Discovery |
Arca Biopharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Arca Biopharma FAQs
-
When was Arca Biopharma founded?
Arca Biopharma was founded in 1992.
-
Where is Arca Biopharma headquartered?
Arca Biopharma is headquartered in Westminster, CO.
-
What is the size of Arca Biopharma?
Arca Biopharma has 5 total employees.
-
What industry is Arca Biopharma in?
Arca Biopharma’s primary industry is Drug Discovery.
-
Is Arca Biopharma a private or public company?
Arca Biopharma is a Private company.
-
What is Arca Biopharma’s current revenue?
The current revenue for Arca Biopharma is .
-
How much funding has Arca Biopharma raised over time?
Arca Biopharma has raised $100M.
-
Who are Arca Biopharma’s investors?
Atlas Venture, Boulder Ventures, InterWest Partners, New Enterprise Associates, and New Leaf Venture are 5 of 15 investors who have invested in Arca Biopharma.
-
Who are Arca Biopharma’s competitors?
CytoAgents, Gilead, Ability Pharma, CyTuVax, and Merck & Co. are some of the 11 competitors of Arca Biopharma.
-
When was Arca Biopharma acquired?
Arca Biopharma was acquired on 29-Aug-2024.
-
Who acquired Arca Biopharma?
Arca Biopharma was acquired by Oruka Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process